| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5633352 | NOVO NORDISK INC | Biosynthetic human growth hormone |
May, 2014
(9 years ago) | |
| US5849704 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2015
(8 years ago) | |
| US5849700 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2015
(8 years ago) | |
Norditropin is owned by Novo Nordisk Inc.
Norditropin contains Somatropin Recombinant.
Norditropin has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Norditropin are:
- US5633352
- US5849704
- US5849700
Norditropin was authorised for market use on 23 January, 2015.
Norditropin is available in injectable;injection dosage forms.
Norditropin can be used as the long term treatment of growth failure due to lack of adequate endogenous growth hormone secretion in children.
The generics of Norditropin are possible to be released after 15 December, 2015.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-572) | Oct 31, 2011 |
| Orphan Drug Exclusivity(ODE) | May 31, 2014 |
Drugs and Companies using SOMATROPIN RECOMBINANT ingredient
Market Authorisation Date: 23 January, 2015
Treatment: The long term treatment of growth failure due to lack of adequate endogenous growth hormone secretion in children
Dosage: INJECTABLE;INJECTION
NORDITROPIN family patents
